(Q38221358)

31 August 2017

title

The use of non-narcotic pain medication in pediatric gastroenterology (English)

1 reference

31 August 2017

1 reference

Adrian Miranda

1

1 reference

31 August 2017

Miguel Saps

series ordinal

2

1 reference

31 August 2017

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

16

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

293-307

1 reference

Prevalence of pain-predominant functional gastrointestinal disorders and somatic symptoms in patients with anxiety or depressive disorders

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Irritable bowel syndrome in female patients is associated with alterations in structural brain networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Altered colorectal afferent function associated with TNBS-induced visceral hypersensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Long-term potentiation in spinal nociceptive pathways as a novel target for pain therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Peripheral and central mechanisms of visceral sensitization in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Childhood functional gastrointestinal disorders: child/adolescent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Quality of life for children with functional abdominal pain: a comparison study of patients' and parents' perceptions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Autonomic nervous system function in young children with functional abdominal pain or irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Unexplained gastrointestinal symptoms and joint hypermobility: is connective tissue the missing link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The overlap of functional abdominal pain in pediatric Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

High prevalence of nausea in children with pain-associated functional gastrointestinal disorders: are Rome criteria applicable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

A prospective school-based study of abdominal pain and other common somatic complaints in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Chronic abdominal pain in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Systematic review: the economic impact of irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Chronic Abdominal Pain In Children: a Technical Report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Prevalence of complementary and alternative medicine (CAM) use by the general population: a systematic review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

A systematic review of sleep in pediatric pain populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

A meta-analysis of the therapeutic effects of amitriptyline for treating irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Long-term efficacy of low-dose tricyclic antidepressants for children with functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Altered rectal sensory response induced by balloon distention in patients with functional abdominal pain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Central and peripheral hypersensitivity in the irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Alterations in rectal sensitivity and motility in childhood irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Involvement of N-methyl-d-aspartate (NMDA) receptors in a rat model of visceral hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Formalin-induced changes of NMDA receptor subunit expression in the spinal cord of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Phosphorylated CaMKII post-synaptic binding to NR2B subunits in the anterior cingulate cortex mediates visceral pain in visceral hypersensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Alterations in N-methyl-D-aspartate receptor subunits in primary sensory neurons following acid-induced esophagitis in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

QT interval and antidepressant use: a cross sectional study of electronic health records

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Significance of screening electrocardiogram before the initiation of amitriptyline therapy in children with functional abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Cyclic antidepressants and the risk of sudden cardiac death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effects of Food and Drug Administration warnings on antidepressant use in a national sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Neuropathic agents and pain. New strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Antidepressant agents for the treatment of chronic pain and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Mechanisms of analgesia by gabapentin and pregabalin--calcium channel alpha2-delta [Cavalpha2-delta] ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Immunostaining of rat brain, spinal cord, sensory neurons and skeletal muscle for calcium channel alpha2-delta (alpha2-delta) type 1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Selective inhibitory effects of pregabalin on peripheral C but not A-delta fibers mediated nociception in intact and spinalized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Gabapentin inhibits excitatory synaptic transmission in the hyperalgesic spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effects of gabapentin and pregabalin on K+-evoked 3H-GABA and 3H-glutamate release from human neocortical synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Neurotransmitter mechanisms in gabapentin antinociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Gabapentin markedly reduces acetic acid-induced visceral nociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The antinociceptive effects of anticonvulsants in a mouse visceral pain model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pregabalin inhibits accelerated defecation and decreased colonic nociceptive threshold in sensitized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effects of pregabalin on visceral pain responses and colonic compliance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effect of nor-trimebutine on neuronal activation induced by a noxious stimulus or an acute colonic inflammation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Lubiprostone does not influence visceral pain thresholds in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Lubiprostone for the treatment of functional constipation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Gastrointestinal clinical pharmacology of peppermint oil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Effect of acute peppermint oil administration on gastric sensorimotor function and nutrient tolerance in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Efficacy of melatonin in the treatment of endometriosis: a phase II, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Analgesic and sedative effects of melatonin in temporomandibular disorders: a double-blind, randomized, parallel-group, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

The effect of melatonin in patients with fibromyalgia: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Melatonin to prevent migraine or tension-type headache in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Gene expression and functional characterization of melatonin receptors in the spinal cord of the rat: implications for pain modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Changes in circadian rhythm for mRNA expression of melatonin 1A and 1B receptors in the hypothalamus under a neuropathic pain-like state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Melatonin: a hormone that modulates pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Studies on the anti-inflammatory and anti-nociceptive effects of melatonin in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-014-0080-6

Melatonin reversal of lipopolysacharides-induced thermal and behavioral hyperalgesia in mice

21 January 2018

1 reference

12 December 2020

A comparative study of loratadine syrup and cyproheptadine HCL solution for treating perennial allergic rhinitis in Taiwanese children aged 2-12 years

1 reference

12 December 2020

Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results

1 reference

12 December 2020

Melatonin for the management of sleep disorders in children and adolescents

1 reference

12 December 2020

Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men

1 reference

12 December 2020

Patients with irritable bowel syndrome and dysmotility express antibodies against gonadotropin-releasing hormone in serum

1 reference

12 December 2020

Visceral hyperalgesia in children with functional abdominal pain

1 reference

12 December 2020

Cow's-milk allergy is a risk factor for the development of FGIDs in children

1 reference

12 December 2020

Sleep disturbances in clinic patients with functional bowel disorders

1 reference

12 December 2020

Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome

1 reference

12 December 2020

Effect of melatonin on release of beta-endorphin, norepinephrine and 5-hydroxytryptamine in rat brain

1 reference

12 December 2020

Psychological and physical stress induce differential effects on human colonic motility

1 reference

12 December 2020

Exogenous melatonin abolishes mechanical allodynia but not thermal hyperalgesia in neuropathic pain. The role of the opioid system and benzodiazepine-gabaergic mechanism.

1 reference

12 December 2020

STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study

1 reference

12 December 2020

Abdominal pain and functional gastrointestinal disorders in children with celiac disease

1 reference

12 December 2020

Therapeutic effect of melatonin in patients with functional dyspepsia

1 reference

12 December 2020

Meta-analysis: melatonin for the treatment of primary sleep disorders

1 reference

12 December 2020

The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels

1 reference

12 December 2020

Adjuvant use of melatonin for treatment of fibromyalgia

1 reference

12 December 2020

Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children

1 reference

12 December 2020

Consensus statement on depression, anxiety, and functional gastrointestinal disorders.

1 reference

12 December 2020

Thirty four years since the discovery of gastrointestinal melatonin

1 reference

12 December 2020

Efficacy and safety of gabapentin for treatment of postherpetic neuralgia: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

The mechanism of action of peppermint oil on gastrointestinal smooth muscle. An analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig

1 reference

12 December 2020

Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome

1 reference

12 December 2020

Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial

1 reference

12 December 2020

Is visceral hypersensitivity correlated with symptom severity in children with functional gastrointestinal disorders?

1 reference

12 December 2020

Central neural mechanisms mediating human visceral hypersensitivity.

1 reference

12 December 2020

Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)

1 reference

12 December 2020

Melatonin administration reduces inflammatory pain in rats

1 reference

12 December 2020

Irritable bowel syndrome patients show enhanced modulation of visceral perception by auditory stress.

1 reference

12 December 2020

Blockade of Nav1.8 currents in nociceptive trigeminal neurons contributes to anti-trigeminovascular nociceptive effect of amitriptyline

1 reference

12 December 2020

10.1007/S40272-014-0080-6

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1004213622

0 references

1 reference